Ameritas Advisory Services LLC Has $389,000 Stake in 10x Genomics, Inc. (NASDAQ:TXG)

Ameritas Advisory Services LLC reduced its stake in 10x Genomics, Inc. (NASDAQ:TXG) by 21.3% in the 2nd quarter, Holdings Channel reports. The firm owned 20,000 shares of the company’s stock after selling 5,417 shares during the period. Ameritas Advisory Services LLC’s holdings in 10x Genomics were worth $389,000 as of its most recent filing with the SEC.

A number of other large investors have also recently added to or reduced their stakes in TXG. Allspring Global Investments Holdings LLC boosted its holdings in 10x Genomics by 113.5% during the first quarter. Allspring Global Investments Holdings LLC now owns 698 shares of the company’s stock valued at $26,000 after acquiring an additional 371 shares during the period. First Horizon Advisors Inc. grew its position in 10x Genomics by 74.1% during the second quarter. First Horizon Advisors Inc. now owns 1,898 shares of the company’s stock worth $37,000 after buying an additional 808 shares in the last quarter. Covestor Ltd increased its stake in 10x Genomics by 501.7% during the first quarter. Covestor Ltd now owns 1,047 shares of the company’s stock valued at $39,000 after acquiring an additional 873 shares during the period. Headlands Technologies LLC acquired a new position in 10x Genomics in the 1st quarter valued at approximately $71,000. Finally, Van ECK Associates Corp lifted its position in shares of 10x Genomics by 23.4% in the 4th quarter. Van ECK Associates Corp now owns 1,908 shares of the company’s stock worth $107,000 after acquiring an additional 362 shares during the period. Institutional investors own 84.68% of the company’s stock.

Insider Activity at 10x Genomics

In other news, insider Benjamin J. Hindson sold 4,351 shares of the stock in a transaction that occurred on Thursday, August 22nd. The shares were sold at an average price of $22.53, for a total transaction of $98,028.03. Following the sale, the insider now directly owns 345,704 shares of the company’s stock, valued at $7,788,711.12. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In other 10x Genomics news, CEO Serge Saxonov sold 6,749 shares of the firm’s stock in a transaction dated Thursday, August 22nd. The stock was sold at an average price of $22.53, for a total transaction of $152,054.97. Following the transaction, the chief executive officer now owns 882,467 shares in the company, valued at $19,881,981.51. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, insider Benjamin J. Hindson sold 4,351 shares of 10x Genomics stock in a transaction that occurred on Thursday, August 22nd. The stock was sold at an average price of $22.53, for a total transaction of $98,028.03. Following the transaction, the insider now directly owns 345,704 shares in the company, valued at approximately $7,788,711.12. The disclosure for this sale can be found here. Insiders sold 14,061 shares of company stock valued at $316,794 over the last ninety days. 10.03% of the stock is owned by insiders.

10x Genomics Price Performance

Shares of TXG opened at $23.35 on Friday. The business’s 50 day simple moving average is $19.88 and its 200-day simple moving average is $27.89. 10x Genomics, Inc. has a one year low of $15.28 and a one year high of $57.90. The company has a market capitalization of $2.81 billion, a P/E ratio of -10.47 and a beta of 1.84.

Wall Street Analysts Forecast Growth

A number of analysts have recently issued reports on TXG shares. Barclays lowered their price objective on 10x Genomics from $36.00 to $24.00 and set an “overweight” rating on the stock in a research report on Friday, June 28th. JPMorgan Chase & Co. cut shares of 10x Genomics from an “overweight” rating to a “neutral” rating and dropped their price objective for the company from $40.00 to $20.00 in a research note on Thursday, July 18th. Wolfe Research reaffirmed a “peer perform” rating on shares of 10x Genomics in a report on Thursday, June 27th. Guggenheim reissued a “neutral” rating on shares of 10x Genomics in a research note on Tuesday, June 25th. Finally, Morgan Stanley cut their price target on shares of 10x Genomics from $50.00 to $46.00 and set an “overweight” rating for the company in a research note on Tuesday, August 13th. One equities research analyst has rated the stock with a sell rating, seven have assigned a hold rating and five have assigned a buy rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $31.46.

10x Genomics Company Profile

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.